Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

Key Stats

Today's Range
$32.48
$32.48
50-Day Range
$32.18
$32.48
52-Week Range
$7.26
$32.50
Volume
73 shs
Average Volume
4.11 million shs
Market Capitalization
$3.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.50
Consensus Rating
Hold

Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CymaBay Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
18th Percentile Overall Score

CBAY MarketRank™: 

CymaBay Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 917th out of 1,004 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CymaBay Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 11 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CymaBay Therapeutics has received no research coverage in the past 90 days.

  • Read more about CymaBay Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CymaBay Therapeutics has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CBAY.
  • Dividend Yield

    CymaBay Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CymaBay Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CBAY.
    • Insider Buying vs. Insider Selling

      In the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 7.00% of the stock of CymaBay Therapeutics is held by insiders.

    • Percentage Held by Institutions

      95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about CymaBay Therapeutics' insider trading history.
    Receive CBAY Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    CBAY Stock News Headlines

    CRUSHED: How Biden's Replacement Will Devastate Your 401(k)!
    Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
    Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
    CBAY Jul 2024 34.000 call
    CBAY Apr 2024 31.000 put
    CBAY Oct 2024 33.000 call
    See More Headlines

    CBAY Stock Analysis - Frequently Asked Questions

    CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.42 million.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CymaBay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

    Company Calendar

    Last Earnings
    2/28/2024
    Today
    10/11/2024
    Fiscal Year End
    12/31/2024

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:CBAY
    Employees
    101
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $32.50
    High Stock Price Target
    $32.50
    Low Stock Price Target
    $32.50
    Potential Upside/Downside
    +0.1%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    11 Analysts

    Profitability

    Net Income
    $-105,370,000.00
    Pretax Margin
    -339.11%

    Debt

    Sales & Book Value

    Annual Sales
    $31.07 million
    Book Value
    $2.58 per share

    Miscellaneous

    Free Float
    106,693,000
    Market Cap
    $3.73 billion
    Optionable
    Optionable
    Beta
    0.32
    The Best High-Yield Dividend Stocks for 2024 Cover

    Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

    Get This Free Report

    This page (NASDAQ:CBAY) was last updated on 10/11/2024 by MarketBeat.com Staff
    From Our Partners